etoposide has been researched along with nu 7441 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cockcroft, X; Curtin, NJ; El-Murr, MD; Golding, BT; Griffin, RJ; Hardcastle, IR; Leahy, JJ; Richardson, C; Rigoreau, L; Smith, GC; Stockley, M | 1 |
| Batey, MA; Calvert, AH; Cowell, IG; Curtin, NJ; Griffin, RJ; Newell, DR; Richardson, CJ; Smith, GC; Thomas, HD; Zhao, Y | 1 |
| Galita, G; Kopa, P; Macieja, A; Majsterek, I; Pastwa, E; Poplawski, T | 1 |
| Gulbas, I; Kopa, P; Macieja, A; Pastwa, E; Poplawski, T | 1 |
| Kopa, P; Macieja, A; Majsterek, I; Pastwa, E; Poplawski, T | 1 |
| Chao, OS; Goodman, OB | 1 |
6 other study(ies) available for etoposide and nu 7441
| Article | Year |
|---|---|
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzopyrans; Binding Sites; Chromones; Combinatorial Chemistry Techniques; DNA-Activated Protein Kinase; Drug Synergism; Etoposide; HeLa Cells; Humans; Morpholines; Radiation-Sensitizing Agents; Radiation, Ionizing; Structure-Activity Relationship; Thiophenes | 2005 |
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; CHO Cells; Chromones; Colorectal Neoplasms; Cricetinae; DNA Damage; DNA-Activated Protein Kinase; Drug Synergism; Etoposide; Female; Histones; Humans; Mice; Mice, Nude; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Radiation-Sensitizing Agents; Tissue Distribution; Xenograft Model Antitumor Assays | 2006 |
Comparison of the effect of three different topoisomerase II inhibitors combined with cisplatin in human glioblastoma cells sensitized with double strand break repair inhibitors.
Topics: Apoptosis; Benzamides; Brain Neoplasms; Cannabidiol; Cell Cycle; Cell Line, Tumor; Chromones; Cisplatin; DNA Breaks, Double-Stranded; DNA Repair; Etoposide; Glioblastoma; Humans; Morpholines; Phenanthrenes; Sulfonamides; Topoisomerase II Inhibitors | 2019 |
Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Chromones; DNA-Activated Protein Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Etoposide; Glioblastoma; Humans; Morpholines; Phenanthrenes | 2020 |
DNA double-strand breaks repair inhibitors potentiates the combined effect of VP-16 and CDDP in human colorectal adenocarcinoma (LoVo) cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromones; Cisplatin; Comet Assay; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Fragmentation; DNA, Neoplasm; Drug Synergism; Epithelial Cells; Etoposide; Histones; Humans; Morpholines; Pyrimidines; Schiff Bases | 2021 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |